ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Programs: Institute Partners With Two Groups On Psychosocial Issues

May 16, 1997

Smokers Who Quit Live Longer Than Those Who Spit-Study

May 25, 2007

Approval Granted For New Formulation of Lupron Depot

July 29, 2011

Cornell, MSKCC, Rockefeller To collaborate In $160M Basic Biological Research Program.

June 30, 2000

GSK Vaccine Prevents Lesions Associated With HPV

July 28, 2006

Anti-Estrogen Drug Therapy Reduces Risk of Invasive Breast Cancer In Older Women

July 25, 2008